Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    86,652.10
    +498.23 (+0.58%)
     

  • CMC Crypto 200

    1,315.85
    +38.87 (+3.04%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Deal Making in Biotech Heating Up

ACCESSWIRE

HENDERSON, NV / ACCESSWIRE / January 9, 2019 / With huge deals biotech and cannabinoid-based companies have been reporting lately, the space looks poised for a big 2019.

One we like is cannabinoid-based biotech firm a, OWC Pharmaceutical Research Corp. (OWCP). OWCP is positioned in multi billion of market opportunity between their two products, one is a pain-relieving soluble tablet, the other a topical cream set to combat conditions like Psoriasis. OWCP is well positioned in two major markets and could take off once it gets more market recognition. Do your due diligence today on OWCP.

Today we are highlighting: OWC Pharmaceutical Research Corp. (OWCP), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), Cronos Group, Inc. (CRON), and Tilray, Inc. (TLRY).

OWC Pharmaceutical Research Corp. (OWCP) (Market Cap: $24.17M Share Price: $0.16) a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, has successfully produced its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as smoking substitute. OWCP will now be able to begin its clinical testing program for this dosing form. OWCP has received an IRB approval to conduct a pharmaco-kinetic (PK) safety study of its sublingual tablet.

ADVERTISEMENT

OWCP is also developing a cannabis-based topical ointment that recently completed recruitment of its last patient for its first ever safety study, conducted at Sheba Medical Center, Tel Hashomer, Israel. The company also reported recently that it has been granted a patent in the Czech Republic covering its topical formulations for skin disorders.

OWCP's multiple products makes them desirable to a wider variety of larger companies, at this stage the company is worth a serious look.

------

Bristol-Myers Squib made a deal to purchase Celgene Corporation (CELG) (Market Cap: $56.36B Share Price: $84.90). CELG investors will receive one Bristol-Myers share and $50 in cash for each Celgene holding, as well as a special rights issue that will pay off if the merged group meets certain business targets. The deal values the cancer drug specialist at $74 billion.

____

Bristol-Myers Squibb Company (BMY) (Market Cap: $76.53B Share Price: $46.89) made major waves on Wall Street Thursday with the buyout of Celgene.

------

A cannabinoid-based biotech firm like OWCP recently receiving major investment dollars, Cronos Group, Inc. (NASDAQ CRON) (Market Cap: $2.12B Share Price: $11.78) has received over $14 billion from Altria for a 45% stake in the company.

____

Tilray, Inc. (TLRY) (Market Cap: $6.51B Share Price: $69.95) recently announced a partnership with beverage giant and the world's largest beer maker, AB InBev (BUD) to research cannabis infused drinks.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a one month term consulting agreement with OWCP dated 12/25/18. The agreement calls for $20,000 in cash per month. All payments were made directly by OWC Pharmaceutical Research, Corp. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. OWCP was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communications, LLC